IP Library › Granted Patent US 9,624,284
Granted Patent B2
US 9,624,284 · App. 14/344,048 · Granted Apr 18, 2017

Cytotoxic T lymphocyte inducing immunogens for prevention treatment and diagnosis of cancer

Inventor: Ramila Philip (Ivyland, PA)
Assignee: Immunotope, Inc.
C07K14/4748A61K38/191A61K38/193A61K38/2006A61K38/208A61K38/2013A61K38/2046A61K38/2086A61K39/0011C07K7/06C07K14/70539A61K2039/55566
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,624,284
App. No.
14/344,048
Granted
Apr 18, 2017
Kind
B2
Abstract

The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as pancreatic carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against pancreatic and other cancers.

Claims (12)

1. A composition for use in a method of:

(a) eliciting a CTL response against tumor cells presenting an epitopic peptide SEQ ID NO: 04 by administration of a sufficient amount of SEQ ID NO: 04, SEQ ID NO: 46 peptides and a stabilizing agent wherein said peptides are in a stable form in the presence of said stabilizing agent in a subject; or

(b) stimulating an immune response in an immunologically competent animal, said composition consisting of SEQ ID NO: 04 and a stabilizing agent capable of facilitating an immune response thereof.

2. The composition for use in a method of claim 1 , wherein said composition further comprises an adjuvant, optionally wherein said adjuvant is selected from the group consisting of complete Freund's adjuvant, incomplete Freund's adjuvant, Montanide ISA-51, LAG-3, aluminum phosphate, aluminum hydroxide, alum, and saponin.

3. The composition for use in a method of claim 1 , wherein said composition further comprises a cytokine, optionally wherein said cytokine is selected from the group consisting of IL-1, IL-2, IL-7, IL-12, IL-15, TNF, SCF and GM-CSF.

4. The composition for use in a method of claim 1 , wherein said composition further comprises a vehicle, optionally wherein said vehicle is selected from the group consisting of a liposome, nanoparticles, an immunostimulating complex (ISCOM), and slow-releasing particles.

5. The composition for use in a method of claim 4 , wherein said liposome comprises an emulsion, a foam, a micelle, an insoluble monolayer, a liquid crystal, a phospholipid dispersion, or a lamellar layer.

6. The composition for use in a method of claim 1 , wherein said tumor cells are part of a carcinoma.

7. The composition for use in a method of claim 6 , wherein said tumor cells are part of a ovarian carcinoma.

8. A composition for use in a method of:

(a) eliciting a CTL response against tumor cells presenting an epitopic peptide SEQ ID NO: 04 by administration of a sufficient amount of SEQ ID NO: 04 linked through a non-conventional peptide bond to an additional peptide sequence and a stabilizing agent wherein said peptides are in a stable form in the presence of the stabilizing agent in a subject; or

(b) stimulating an immune response in an immunologically competent animal, said composition consisting of SEQ ID NO: 04 and a stabilizing agent capable of facilitating an immune response thereof.

Continuity (3)
Provisional Application 61533852 · Sep 13, 2011
Provisional Application 61611725 · Mar 16, 2012
Related Publication 20140220117A1 · Aug 7, 2014